Moleculin Biotech (MBRX) CEO reports RSU vesting, tax-share withholding and retained stake
Rhea-AI Filing Summary
Moleculin Biotech, Inc. CEO and President Walter V. Klemp reported routine equity compensation activity involving restricted stock units and related tax withholding. On June 20 and June 22, restricted stock units converted into a total of 510 shares of common stock at a conversion price of $0.00 per share. To cover tax obligations on these vestings, a total of 125 common shares were disposed of via tax-withholding transactions, rather than open-market sales. After these transactions, Klemp directly held 31,007 shares of common stock and continued to hold a substantial equity position through 326,336 restricted stock units, as well as 250,002 shares of common stock underlying Series E warrants.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 385 shares
Net Buy
6 txns
Insider
KLEMP WALTER V
Role
CEO and President
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 360 | $0.00 | $0.00 |
| Exercise | Common Stock | 360 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 88 | $3.12 | $274.56 |
| Exercise | Restricted Stock Units | 150 | $0.00 | $0.00 |
| Exercise | Common Stock | 150 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 37 | $2.88 | $106.56 |
Holdings After Transaction:
Restricted Stock Units — 326,336 shares (Direct);
Common Stock — 31,007 shares (Direct)
Footnotes (5)
- F1. Restricted stock units convert into common stock on a one-for-one basis.
- F2. Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
- F3. On June 20, 2022, the reporting person was granted 600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
- F4. On June 22, 2023, the reporting person was granted 1,439 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
- F5. Includes 250,002 shares of common stock underlying Series E warrants to purchase common stock.
Key Figures
RSU conversions: 510 shares
Tax-withheld shares: 125 shares
Common shares held: 31,007 shares
+3 more
6 metrics
RSU conversions
510 shares
Restricted stock units converted into common stock on June 20 and June 22
Tax-withheld shares
125 shares
Common shares delivered to cover tax liabilities on RSU vesting
Common shares held
31,007 shares
Direct common stock holdings after transactions
RSUs outstanding
326,336 units
Restricted stock units remaining after reported conversions
Series E warrants underlying
250,002 shares
Shares of common stock underlying Series E warrants
Tax disposition prices
$3.12 and $2.88 per share
Prices for shares delivered to cover tax liabilities
Key Terms
Restricted stock units, tax-withholding disposition, derivative security, Series E warrants
4 terms
Restricted stock units financial
"Restricted stock units convert into common stock on a one-for-one basis."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax-withholding disposition financial
"Payment of exercise price or tax liability by delivering securities"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Series E warrants financial
"Includes 250,002 shares of common stock underlying Series E warrants to purchase common stock."
FAQ
What insider transactions did Moleculin Biotech (MBRX) report for its CEO?
Moleculin Biotech CEO Walter V. Klemp reported routine equity compensation activity. Restricted stock units converted into 510 common shares, and 125 shares were withheld to cover taxes, with no open-market purchases or sales disclosed.
What are the CEO’s Moleculin Biotech (MBRX) common stock holdings after these transactions?
Following the reported transactions, Walter V. Klemp directly held 31,007 shares of Moleculin Biotech common stock. This figure reflects his position after both the restricted stock unit conversions and the related tax-withholding share dispositions.
What derivative equity interests in Moleculin Biotech (MBRX) does the CEO still hold?
After the reported vestings, Walter V. Klemp continued to hold 326,336 restricted stock units and 250,002 shares of common stock underlying Series E warrants. These instruments provide additional potential equity exposure beyond his directly held common shares.
Were the Moleculin Biotech (MBRX) insider transactions open-market buys or sells?
The filing shows derivative exercises of restricted stock units into common shares and tax-withholding dispositions. The transactions involve equity awards vesting and shares delivered for taxes, rather than discretionary open-market purchases or sales by the CEO.
AI-generated analysis. How Rhea-AI works. Not financial advice.
